Neuren Pharmaceuticals Limited Stock Return On Equity
| NURPF Stock | USD 12.51 0.02 0.16% |
Neuren Pharmaceuticals Limited fundamentals help investors to digest information that contributes to Neuren Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Neuren Pink Sheet. The fundamental analysis module provides a way to measure Neuren Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neuren Pharmaceuticals pink sheet.
Neuren |
Neuren Pharmaceuticals Limited Company Return On Equity Analysis
Neuren Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Neuren Pharmaceuticals Return On Equity | -0.27 |
Most of Neuren Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neuren Pharmaceuticals Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Neuren Pharmaceuticals Limited has a Return On Equity of -0.2746. This is 98.85% lower than that of the Healthcare sector and 99.25% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 11.42% lower than that of the firm.
Neuren Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neuren Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Neuren Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Neuren Pharmaceuticals by comparing valuation metrics of similar companies.Neuren Pharmaceuticals is currently under evaluation in return on equity category among related companies.
Neuren Fundamentals
| Return On Equity | -0.27 | |||
| Return On Asset | -0.17 | |||
| Profit Margin | (2.15) % | |||
| Operating Margin | (2.31) % | |||
| Current Valuation | 602.02 M | |||
| Shares Outstanding | 128.97 M | |||
| Shares Owned By Insiders | 16.48 % | |||
| Shares Owned By Institutions | 9.41 % | |||
| Price To Earning | 49.75 X | |||
| Price To Book | 27.96 X | |||
| Price To Sales | 203.95 X | |||
| Revenue | 3.2 M | |||
| Gross Profit | (6.32 M) | |||
| EBITDA | (11.43 M) | |||
| Net Income | (7.79 M) | |||
| Cash And Equivalents | 31.09 M | |||
| Cash Per Share | 0.25 X | |||
| Current Ratio | 31.54 X | |||
| Book Value Per Share | 0.27 X | |||
| Cash Flow From Operations | (9.97 M) | |||
| Earnings Per Share | (0.05) X | |||
| Number Of Employees | 15 | |||
| Beta | 1.5 | |||
| Market Capitalization | 660.11 M | |||
| Total Asset | 40.06 M | |||
| Retained Earnings | (97 M) | |||
| Working Capital | 7 M | |||
| Current Asset | 9 M | |||
| Current Liabilities | 2 M | |||
| Z Score | -2.8 | |||
| Net Asset | 40.06 M |
About Neuren Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neuren Pharmaceuticals Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neuren Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neuren Pharmaceuticals Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Neuren Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Neuren Pharmaceuticals' short interest history, or implied volatility extrapolated from Neuren Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuren Pharmaceuticals Limited. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Neuren Pink Sheet analysis
When running Neuren Pharmaceuticals' price analysis, check to measure Neuren Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuren Pharmaceuticals is operating at the current time. Most of Neuren Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Neuren Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuren Pharmaceuticals' price. Additionally, you may evaluate how the addition of Neuren Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |